HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Yuechi active pharmaceutical ingredients

In multistep synthesis the hardest question is often why the impurity profile shifted, not the main assay. The inquiry follows starting materials, reaction, extraction, crystallisation, drying, solvent recovery, analytical methods and lot release to a named substance.

Formation and regional foundations

Yuechi combines a compliant park with shared pilot and analytical facilities. A pilot platform proves scale-up service, a production licence limits manufacturing, and API registration belongs to a substance; none replaces another.

The inquiry separates process development, licensed production and market supply. A substance entering pilot scale is not proof of licence or commercial output.

Core geography: The boundary includes licensed Yuechi synthetic or fermented active ingredients, pharmaceutical intermediates, pilot scale-up, analytical testing and solvent recovery. Finished-drug brands, aesthetics, devices, investment intentions and unlicensed projects are not API capacity.

From starting material to API lot release

Six reaction, purification and analytical nodes

Substance, licence, process and method must share a revision.

  • Starting materials — Identity, purity and supplier lot are approved first.
  • Multistep reaction — Charge, temperature, time and endpoint are recorded by step.
  • Extraction and washing — Phase split, pH and solvent recovery control carryover.
  • Crystallisation and filtration — Form, particle size and mother liquor set purification.
  • Drying and packing — Moisture, residual solvent and environment bind to lot.
  • Analysis and lot release — Assay, impurities, method and deviations are reviewed together.

01 · Find the change point in the impurity profile

A changed peak does not prove the main reaction failed.

A rise in an unknown impurity for one substance can come from starting material, side reaction, degradation, residual solvent or the analytical system.

The investigation first compares lot timelines and raw chromatograms before choosing where to resample; final assay does not replace cause analysis.

Registration standard, internal limits and method revision must belong to the same substance; a related compound’s limits cannot be borrowed.

02 · Starting materials set impurity potential

A supplier change is not an ordinary purchase change.

A starting material’s route, residual reagents and isomers enter downstream impurity risk; identical names do not mean identical quality histories.

A new supplier needs sample evaluation, audit and suitability lots, with regulatory impact assessed against filings and licences.

Retest date, storage conditions and sampling tools also affect incoming conclusions; a certificate cannot replace site confirmation.

03 · Reaction endpoint is not a fixed clock

Temperature, charge and in-process sample decide together.

Charge order, heating rate, agitation and hold time in multistep synthesis change conversion and side-reaction ratios.

Endpoint uses an approved method and sampling location; scheduled time alone may stop with unreacted material or after degradation begins.

A reaction deviation needs actual curves, operations and equipment state, not one retrospective sentence in the batch record.

04 · Extraction controls carryover and loss

A clear phase split does not prove purification.

pH, solvent ratio, temperature and settling time affect product partition as well as emulsion and mother-liquor carryover.

When phase boundaries rely on visual observation, lighting, sight glass and discharge rate need standardisation, with disposition of abnormal layers recorded.

Recovered solvent is reused only when purity, water and impurities meet approved conditions; cycle count and destination follow the lot.

05 · Crystallisation turns purity into a solid form

Addition, supersaturation and seed act together.

Solvent composition, cooling curve, addition rate and seed condition change form, particle distribution and impurity rejection to mother liquor.

Filtration pressure and wash volume must match cake depth; too little leaves impurities, too much loses yield.

When form or particle size is part of substance quality, scale-up requires approved-method confirmation rather than appearance.

06 · Drying also controls degradation

Good moisture does not settle residual solvent.

Vacuum, temperature, turning and time remove moisture and solvent but can also cause thermal degradation or form change.

Sampling locations must cover dryer variation; local acceptance before blending does not prove lot uniformity.

Environment, utensils and personnel cleanliness during dry transfer and inner packing enter the batch record to prevent late contamination.

07 · Analytical methods also need validation

An instrument peak is not automatically a real impurity.

Specificity, linearity, precision, recovery and quantitation limit determine whether the method resolves target impurities; system suitability is only one gate.

Reference lot, solution stability, integration rules and column change can move results, so review starts with raw data.

A shared analytical platform provides testing capability, while the sponsor remains responsible for method transfer, sample representativeness and final verdict.

08 · Release rests on three evidence lines

Pilot, licence and registration are not interchangeable.

A pilot platform proves route and scale-up service, a production licence says what an entity may make, and registration belongs to a substance.

Renan, Pukang and Yujian each have specific project and product evidence; one firm’s approved substance cannot be lent to another.

Yuechi firm counts and output show regional concentration; they do not mean every project operates or prove one lot’s quality.

Sources and reading notes

Yuechi and Guangan records, environmental files and the national medicine registry verify park, entities, processes and substance status. Assessed design capacity is not actual output, and a research pipeline is not a marketed product.

  • Yuechi public records list 21 pharmaceutical-intermediate and API firms.
  • The cited group includes nine national top-100 pharmaceutical firms.
  • The same source records seven listed pharmaceutical firms among the related park entities.
  • The source records CNY 1.31 billion in related output from January through July 2025.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.